Literature DB >> 25907631

The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.

Kjetil H Egge1, Andreas Barratt-Due1, Stig Nymo2, Julie K Lindstad1, Anne Pharo1, Corinna Lau2, Terje Espevik3, Ebbe B Thorgersen1, Tom E Mollnes1,2,3.   

Abstract

Combined inhibition of complement and CD14 is known to attenuate bacterial-induced inflammation, but the dependency of the bacterial load on this effect is unknown. Thus, we investigated whether the effect of such combined inhibition on Escherichia coli- and Staphylococcus aureus-induced inflammation was preserved during increasing bacterial concentrations. Human whole blood was preincubated with anti-CD14, eculizumab (C5-inhibitor) or compstatin (C3-inhibitor), or combinations thereof. Then heat-inactivated bacteria were added at final concentrations of 5 × 10(4) -1 × 10(8) /ml (E. coli) or 5 × 10(7) -4 × 10(8) /ml (S. aureus). Inflammatory markers were measured using enzyme-linked immunosorbent assay (ELISA), multiplex technology and flow cytometry. Combined inhibition of complement and CD14 significantly (P < 0.05) reduced E. coli-induced interleukin (IL)-6 by 40-92% at all bacterial concentrations. IL-1β, IL-8 and macrophage inflammatory protein (MIP)-1α were significantly (P < 0.05) inhibited by 53-100%, and the effect was lost only at the highest bacterial concentration. Tumour necrosis factor (TNF) and MIP-1β were significantly (P < 0.05) reduced by 80-97% at the lowest bacterial concentration. Monocyte and granulocyte CD11b were significantly (P < 0.05) reduced by 63-91% at all bacterial doses. Lactoferrin was significantly (P < 0.05) attenuated to the level of background activity at the lowest bacterial concentration. Similar effects were observed for S. aureus, but the attenuation was, in general, less pronounced. Compared to E. coli, much higher concentrations of S. aureus were required to induce the same cytokine responses. This study demonstrates generally preserved effects of combined complement and CD14 inhibition on Gram-negative and Gram-positive bacterial-induced inflammation during escalating bacterial load. The implications of these findings for future therapy of sepsis are discussed.
© 2015 British Society for Immunology.

Entities:  

Keywords:  CD14; complement; inflammation; sepsis

Mesh:

Substances:

Year:  2015        PMID: 25907631      PMCID: PMC4557382          DOI: 10.1111/cei.12645

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

Review 2.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Authors:  E Abraham; P F Laterre; J Garbino; S Pingleton; T Butler; T Dugernier; B Margolis; K Kudsk; W Zimmerli; P Anderson; M Reynaert; D Lew; W Lesslauer; S Passe; P Cooper; A Burdeska; M Modi; A Leighton; M Salgo; P Van der Auwera
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

4.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

5.  Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved.

Authors:  Nicolas W J Schröder; Siegfried Morath; Christian Alexander; Lutz Hamann; Thomas Hartung; Ulrich Zähringer; Ulf B Göbel; Joerg R Weber; Ralf R Schumann
Journal:  J Biol Chem       Date:  2003-02-19       Impact factor: 5.157

6.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors:  C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

7.  Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin.

Authors:  J A Ember; S D Sanderson; T E Hugli; E L Morgan
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

8.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

9.  Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.

Authors:  T E Mollnes; T Lea; S S Frøland; M Harboe
Journal:  Scand J Immunol       Date:  1985-08       Impact factor: 3.487

10.  Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).

Authors:  T E Mollnes; H Redl; K Høgåsen; A Bengtsson; P Garred; L Speilberg; T Lea; M Oppermann; O Götze; G Schlag
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

View more
  6 in total

1.  Human Endothelial Cell Activation by Escherichia coli and Staphylococcus aureus Is Mediated by TNF and IL-1β Secondarily to Activation of C5 and CD14 in Whole Blood.

Authors:  Stig Nymo; Alice Gustavsen; Per H Nilsson; Corinna Lau; Terje Espevik; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2016-01-22       Impact factor: 5.422

Review 2.  Complement in disease: a defence system turning offensive.

Authors:  Daniel Ricklin; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2016-05-23       Impact factor: 28.314

3.  Complement System Inhibition Modulates the Pro-Inflammatory Effects of a Snake Venom Metalloproteinase.

Authors:  Lygia Samartin Gonçalves Luchini; Giselle Pidde; Carla Cristina Squaiella-Baptistão; Denise V Tambourgi
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561

4.  Defining the optimal animal model for translational research using gene set enrichment analysis.

Authors:  Christopher Weidner; Matthias Steinfath; Elisa Opitz; Michael Oelgeschläger; Gilbert Schönfelder
Journal:  EMBO Mol Med       Date:  2016-08-01       Impact factor: 12.137

5.  Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4-MD2 Complex.

Authors:  Alice Gustavsen; Stig Nymo; Anne Landsem; Dorte Christiansen; Liv Ryan; Harald Husebye; Corinna Lau; Søren E Pischke; John D Lambris; Terje Espevik; Tom E Mollnes
Journal:  J Infect Dis       Date:  2016-03-14       Impact factor: 5.226

6.  NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies.

Authors:  Corinna Lau; Martin Berner McAdam; Grethe Bergseth; Algirdas Grevys; Jack Ansgar Bruun; Judith Krey Ludviksen; Hilde Fure; Terje Espevik; Anders Moen; Jan Terje Andersen; Tom Eirik Mollnes
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.